-
Enabling Delivery and Solving Stability for biologics and mRNA
LaminarPace: a game-changing formulation and drying technology for advanced biologics, enhancing stability and usability of high-potential biotherapeutics.
-
Unlocking mRNA potential
LaminarPace takes RNA therapeutics and mRNA/LNP to the next level. It transforms delicate liquids into robust, storage-friendly powders, opening new drug delivery horizons, free from cryogenic constraints and sustainability burdens.
-
The heat-free advantage: Mass Transfer drying
LaminarPace's unique Mass Transfer drying method avoids extreme temperatures and stress factors, preserving very delicate biological formulations. Discover how we overcome biotherapeutic limitations here.
-
Your partner for biotherapeutics
Our expert team conducts Feasibility and Evaluation studies for industry partners regarding three strategic vaccine platforms: mRNA/LNP, viral vector and protein subunit vaccines to investigate the potential for licensing of LaminarPace to expand your biotherapeutic possibilities.
-
Industrial integration in pharmaceutical production
We are developing LaminarPace to be seamlessly integrated at scale into biopharmaceutical manufacturing as an aseptic, high yield, novel unit of production. In our development we apply cutting edge 3D modelling to simulate and accelerate scaleout and technology optimization.
Press Releases
Upcoming events
Ziccum Updates
Meet Ziccum
Our team combines decades of pharmaceutical experience with extensive expertise in formulation, biochemistry, process engineering and more.
We dry biologics
Ziccum's unique drying and formulation system LaminarPace is a new way of drying biologics. It eliminates heat stress, heat degradation and the need for elevated temperatures. Unlike other pharmaceutical drying systems, LaminarPace uses Mass Transfer, not Heat Transfer, to dry delicate biologics from vaccines to protein therapeutics as particle-engineered powders that are thermostable and highly suitable for novel administration routes.
What is LaminarPace?
Ziccum’s ambient drying technology LaminarPace has successfully dried biomolecules - from mRNA, proteins, vaccines and peptides to antibodies and lipids - as thermostable, particle-engineered powders.
Expanding possibilities for next-generation vaccines and biologics
Our unique ambient drying technology, LaminarPace, dries next-generation vaccines and biologics as particle-engineered powders that are thermostable and also highly suited for novel administration routes.
Explore our Business Model
Ziccum offers licenses and tech transfers to vaccine and biotherapeutics companies based on our patent portfolio and continuous technology development. Our overall objective is to enter into one or more license agreements with one or more major pharmaceutical companies.
Invest in innovation
Innovation in vaccination formulation is growing. Interested in investing? In our Investors section you can Subscribe to regular news updates and explore our Business Model, Portfolio Overview and how ambient drynig can help drive sustainability in vaccine production.
Contact us
Whether you have an enquiry on your development project, are interested in a career in Ziccum, or have a technical question – contact us here.